<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="parameters to equivalently reflect their physiological state. From the virtual" exact="screening" post="results, two drug molecules were selected for each drug"/>
 <result pre="the host immune response which is essential for successful viral" exact="infection" post="(Menachery etÂ al., 2014). This protein can, therefore, act"/>
 <result pre="selection of antiviral drugs against 3CLpro and 2â€²-OMTase PyRx virtual" exact="screening" post="software v0.8 (http://pyrx.sourceforge.net/downloads) was used for the screening of"/>
 <result pre="PyRx virtual screening software v0.8 (http://pyrx.sourceforge.net/downloads) was used for the" exact="screening" post="of antiviral drugs against 3CLpro and 2â€²-OMTase proteins. One"/>
 <result pre="exhaustiveness 32 option was used to carry out the virtual" exact="screening" post="and docking of antiviral drugs against 3CLpro (Grid Box:"/>
 <result pre="and 2). Table 1. Selected drug molecules obtained from virtual" exact="screening" post="of 3CLpro against the in-house library of anti-viral drugs."/>
 <result pre="Inhibition Constant. Table 2. Selected drug molecules obtained from virtual" exact="screening" post="of 2â€²-OMTase against the in-house library of anti-viral drugs."/>
 <result pre="3.2. Screening of anti-viral drugs against 3CLpro and 2â€²-OMTase Virtual" exact="screening" post="is one of the essential tools in drug designing"/>
 <result pre="a target molecule (Kitchen etÂ al., 2004). Also, the virtual" exact="screening" post="tools employ scoring functions to predict the strength of"/>
 <result pre="(Gimeno etÂ al., 2019). PyRx was used for the virtual" exact="screening" post="of antiviral drugs against 3CLpro and 2â€²-OMTase proteins. One"/>
 <result pre="precautionary steps taken by governments all over the world include" exact="social distancing," post="quarantines and lockdowns, which themselves have adverse psychological and"/>
 <result pre="F., GutierrezJ., &amp;amp; MartinP. (2014). New antiviral agents for the" exact="treatment" post="of hepatitis C: ABT-450. Expert Opinion on Pharmacotherapy, 15(5),"/>
 <result pre="FurrJ. R., &amp;amp; BajorathJ. (2004). Docking and scoring in virtual" exact="screening" post="for drug discovery: Methods and applications. Nature Reviews Drug"/>
 <result pre="alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial" exact="treatment" post="of HIV-1 infection (GS-US-380â€&quot;1490): A randomised, double-blind, multicentre, phase"/>
 <result pre="with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1" exact="infection" post="(GS-US-380â€&quot;1490): A randomised, double-blind, multicentre, phase 3, non-inferiority trial."/>
 <result pre="WynneB., MinS., &amp;amp; NicholsG. (2013). Dolutegravir plus abacavirâ€&quot;lamivudine for the" exact="treatment" post="of HIV-1 infection. New England Journal of Medicine, 369(19),"/>
</results>
